Preclinical Evaluation of Puerarin as a Modulator of Metabolic and Inflammatory Parameters in a High-Fat-Diet-Fed Mice Model

Obesity is a multifactorial condition characterized by adipose tissue dysfunction, insulin resistance, and low-grade systemic inflammation, contributing to metabolic disturbances. The search for natural compounds with protective actions against obesity and its complications has attracted increasing attention. Puerarin, an isoflavone derived from Pueraria lobata, has been reported to exert anti-inflammatory and metabolic regulatory properties. This study aimed to evaluate the effects of puerarin, a natural isoflavone, on metabolic and inflammatory alterations in a mouse model of diet-induced obesity. Male C57BL/6 mice were fed a high-fat diet (HFD) and treated orally with puerarin (50 mg/kg) for 14 weeks. The administration of puerarin resulted in a 17% reduction in weight gain, improved glucose tolerance by 6.2%, and decreased insulin resistance by 11% compared to the HFD group. Histological analysis revealed a marked reduction in hepatic steatosis and adipocyte hypertrophy. Additionally, puerarin lowered the concentration of proinflammatory cytokines, including IL-6, TNF-α, IL-1β, IL-17A, and IFN-γ, while increasing IL-10 levels. These findings suggest that puerarin may provide protective effects on glucose metabolism, liver steatosis, and adipose tissue inflammation in obesity, highlighting its possible potential as an immunometabolic modulator.